5Vote!
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...
5Vote!
Fool.com (Free subscription) | yesterday
... target the same molecule could become blockbusters: Abbott Labs' Humira, Johnson & JohnsonMerck Remicade, and PfizerAmgen Enbrel all target TNF-alpha and combined to bring in last year.
+Vote!
Indy Star (Free subscription) | 11/04/2009
Biologic drugs, those made from living organisms instead of from chemicals, are increasingly used to treat arthritis, cancer, diabetes and other diseases. They're also more expensive for drug makers to produce and for patients to buy. The breast cancer drug Herceptin can cost $48,000 a year, and the rheumatoid arthritis drug Remicade can cost about $20,000.
+Vote!
Food and Drug Adminstration (FDA): Patient Safety News (Free subscription) | 11/01/2009
FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humir...
5Vote!
The Philadelphia Business Journal (Free subscription) | 11/03/2009
... unresolved following the merger is Merck’s rights to sales of Centocor’s arthritis medicine Remicade outside of the United States.Schering-Plough acquired those rights from Johnson & Johnson (NYSE:JNJ), which owns Centocor Ortho Biotech of Horsham, Pa. Johnson & Johnson is claiming the merger terminates the deal under a change-of-control provision in its agreement with Schering-Plough.Merck...
4Vote!
AterSlash (Free subscription) | 10/26/2009
Congress seems poised to turn an effort to create a pathway for generic biotech drugs, such as Remicade, into the exact opposite. Instead of the 5-year protection that traditional pharmaceuticals get, or the 0-year protection that the FTC recommends, the bill offers 12-year exclusivity with renewability for minor changes.
5Vote!
Ask Slashdot (Free subscription) | 10/26/2009
linuxizer writes "Congress seems poised to turn an effort to create a pathway for generic biotech drugs, such as Remicade, into the exact opposite. Instead of the 5-year protection that traditional pharmaceuticals get, or the 0-year protection that the FTC recommends, the bill offers 12-year exclusivity with renewability for minor changes. The issue is highly charged, with activists waging...
5Vote!
Click World News (Free subscription) | 10/26/2009
linuxizer writes "Congress seems poised to turn an effort to create a pathway for generic biotech drugs, such as Remicade, into the exact opposite. Instead of the 5-year protection that traditional pharmaceuticals get, or the 0-year protection that the FTC recommends, the bill offers 12-year exclusivity with renewability for minor changes. The issue is highly charged, with activists waging...
3Vote!
Computer Nerds Blog (Free subscription) | 10/26/2009
linuxizer writes "Congress seems poised to turn an effort to create a pathway for generic biotech drugs, such as Remicade, into the exact opposite. Instead of the 5-year protection that traditional pharmaceuticals get, or the 0-year protection that the FTC recommends, the bill offers 12-year exclusivity with renewability for minor changes. The issue is highly charged, with activists waging...
5Vote!
Forbes (Free subscription) | 10/29/2009
Swedish researchers analyzed data from 6,366 rheumatoid arthritis patients who started anti-TNF therapy with infliximab (Remicade), adalimumab (Humira) or etanercept (Enbrel) between January 1999 and July 2006. The study participants were compared with other groups of rheumatoid arthritis patients, including 61,160 not taking medications, 4,015 taking methotrexate (the gold standard of treatment)...
4Vote!
PR News Wire (Free subscription) | 10/22/2009
... States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants. The decline in use for these established drugs will stem from physicians increasing their use of UCB's Cimzia and Centocor Ortho Biotech's Simponi and prescribing only one TNF-alpha inhibitor...
5Vote!
Science Daily (Free subscription) | 10/29/2009
TNF is a cytokine (substance secreted by immune system cells) that regulates the body's immune system and is involved in inflammation. TNF inhibitors (or TNF blockers) are a class of therapies used to reduce inflammation in chronic inflammation such as RA. The common immunosuppressant drugs and those included in the study are Remicade®, HumiraTM, and Enbrel®. As these therapies are used to treat...
3Vote!
Living on the frontlines (Free subscription) | 10/22/2009
... and care or post-op anti rejection drugs. Many HPS'ers require expensive medications such as Remicade at $10,000 an injection every six to eight weeks. Couple that with other complications as life goes on, and once again, the bills start adding up fast. If you feel so moved, please call your Congressional representative and ask them to sign onto this letter to abolish insurance coverage...
5Vote!
Collecting my Thoughts (Free subscription) | 10/14/2009
... takes a weekly oral medication, and every five to six weeks, gets an infusion of a drug called Remicade. Without insurance, the infusions alone would cost around $40,000 a year." So maybe he's rich enough to afford the huge tax increase he'll have to pay, but last year, there were a lot of people who thought they were rich. Then the sub-prime melt down; then Bernie Maddof, etc. Now...
11Vote!
The Huffington Post (Free subscription) | 10/27/2009
... -- or people quickly hit their limits and must pay for it out-of-pocket or go without. Embrel and Remicade, for rheumitoid arthritis, Rituxan, for Non-Hodgkin's lymphpoma, Avasta, for metastatic colorectal cancer, Lantus, for diabetes, and Avonex, for multiple sclerosis, are just a few of these biologics. When I was on chemotheraphy, I took Neulasta to boost my white blood cell count and...
